Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06213233 · ClinicalTrials.gov registry record · Phase 2
MIVetsCan: Cannabidiol (CBD)-Care Trial
A Phase 2 study of Pain, Chronic, sponsored by Kevin Boehnke.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 468
- Enrollment target
- 1
- Study location
NCT06213233: Recruiting Phase 2 study of Pain, Chronic, sponsored by Kevin Boehnke.
NCT06213233 is a Phase 2 study of Pain, Chronic that is actively recruiting participants, run by Kevin Boehnke. The registered enrollment target is 468 participants, below the 712-participant average among 48 other Pain, Chronic trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06213233, a Phase 2 study of Pain, Chronic, is actively recruiting participants, sponsored by Kevin Boehnke.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 468 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is studying the effects of cannabidiol (CBD), an active component from cannabis (a.k.a. marijuana), on Veterans' chronic pain. The purpose of this study is to better understand if CBD can improve pain symptoms in Veterans with chronic pain. Eligible participants will be randomly assigned to receive either placebo medication (not active) or CBD during the study period. The study hypotheses: \- CBD would improve overall pain symptoms compared to placebo
Primary Outcome
This is a 1-item survey that measures patient perceptions of intervention success. This survey is scored from 1 to 7, where lower scores indicate a better outcome.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cannabidiol
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 468 participants |
| Start Date | 2024-02-12 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT06213233 shows while recruiting
NCT06213233 is an interventional study that assigns participants to a tested intervention. The registered 468 participants enrollment target is mid-sized for trials with a published cap, below the 712-participant average among 48 other Pain, Chronic trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Pain, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06213233 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06213233 about?
NCT06213233 is a clinical study titled "MIVetsCan: Cannabidiol (CBD)-Care Trial". This research is studying the effects of cannabidiol (CBD), an active component from cannabis (a.k.a. marijuana), on Veterans' chronic pain. The purpose of this study is to better understand if CBD can improve pain symptoms in Veterans with chronic pain. Eligible participants will be randomly assig...
What is the current status of trial NCT06213233?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 468 participants. The study started on 2024-02-12. Estimated completion is 2026-12.
What conditions does trial NCT06213233 study?
This clinical trial studies the following conditions: Pain, Chronic.
What interventions are being tested in trial NCT06213233?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT06213233?
This trial is sponsored by Kevin Boehnke, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06213233 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06213233's enrollment target sits among peer trials
468 8th of 48 higher than 41 of 48 other Pain, Chronic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain, Chronic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
RECRUITING · Phase 2
-
Pain Reprocessing Therapy in Post-Operative Knee Pain
RECRUITING · Phase 2
-
Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain
RECRUITING · Phase 2
-
Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure
ACTIVE NOT RECRUITING · Phase 2
-
RTMS for Treatment of Pain and Craving
COMPLETED · Phase 2
-
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03124303 · 468 participants
Interventions for Postoperative Delirium: Biomarker-3
- NCT03901924 · 468 participants · NA
Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
- NCT04482309 · 468 participants · Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
- NCT05357170 · 468 participants
Microbiome Dysfunction in Surgical Intensive Care Unit Survivors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI